The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preliminary results from an ongoing phase 2a study of RX-3117, an oral nucleoside analogue to treat advanced urothelial cancer (aUC).
 
Jacob Adashek
No Relationships to Disclose
 
Sumanta K. Pal
Honoraria - Astellas Pharma; Medivation; Novartis
Consulting or Advisory Role - Astellas Pharma; Aveo; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Ipsen; Myriad Pharmaceuticals; Novartis; Pfizer
Research Funding - Medivation
 
Vincent M. Chung
Consulting or Advisory Role - Celgene; Five Prime Therapeutics; Ipsen; Perthera
Speakers' Bureau - Celgene
 
Scott T. Tagawa
Consulting or Advisory Role - Abbvie; Astellas Pharma; Bayer; Dendreon; Endocyte; Genentech; Immunomedics; Janssen; Karyopharm Therapeutics; Medivation; Sanofi; Tolmar
Speakers' Bureau - Amgen
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Newlink Genetics (Inst); Novartis (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst)
Travel, Accommodations, Expenses - Immunomedics; Sanofi
 
Joel Picus
Consulting or Advisory Role - Novo Nordisk
Research Funding - Agensys (Inst); Altor BioScience (Inst); BioClin Therapeutics (Inst); Endocyte (Inst); Innocrin Pharma (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Oncogenex (Inst); Rexahn Pharmaceuticals (Inst); Seagen (Inst)
 
Hani M. Babiker
Consulting or Advisory Role - Celgene; Endocyte
 
Sumati Gupta
Stock and Other Ownership Interests - Salarius Pharmaceuticals (I)
Consulting or Advisory Role - Keryx (I)
Research Funding - Bristol-Myers Squibb (Inst); Five Prime Therapeutics (Inst); Hoosier Cancer Research Network (Inst); Incyte (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Rexahn Pharmaceuticals (Inst); Viralytics (Inst)
Travel, Accommodations, Expenses - Keryx (I)
 
Raymond Couric Wadlow
No Relationships to Disclose
 
Julie Poore
Employment - Rexahn Pharmaceuticals
 
Christine Peterson
Employment - Rexahn Pharmaceuticals
Stock and Other Ownership Interests - Rexahn Pharmaceuticals
 
Ely Benaim
Employment - Rexahn Pharmaceuticals
Leadership - Rexahn Pharmaceuticals
Stock and Other Ownership Interests - Rexahn Pharmaceuticals
Honoraria - Rexahn Pharmaceuticals